BioClinica opens an app umbrella to unite researchers

Clinical trial technology outfit BioClinica has created what it's calling an app exchange, looking for new software that can help physicians and drug developers through the company's cloud-based data service.

Called the BioClinica eHealth App xChange, the CRO's new platform is part of a broader effort to partner with innovative technology companies, eClinical President Mukhtar Ahmed said. The idea is to expand BioClinica's existing tech offerings by looping external app developers, and the company says its client network will help potential partners gain exposure for their technologies.

"BioClinica's eHealth App xChange enables research communities to leverage an ecosystem of integrated mobile and cloud applications for unique patient and consumer engagement, digital medicine, biosensor and scientific analytic capabilities, thereby accelerating pre- and post-approval research while creating efficiency and quality benefits," Ahmed said in a statement. "Our approach introduces pragmatic industry innovation and provides our customers with an integrated and highly interoperable platform that extends across the entire healthcare research landscape."

Meanwhile, the acquisitive BioClinica has been splashing cash to expand its capabilities and grow its market share. Last year, BioClinica acquired Blueprint Clinical and its cloud-based tool for tracking and scoring clinical trial sites. Months before, it bought CCBR-Synarc in a deal that stretched BioClinica's focus to include medical imaging and specialty services for clinical trials.

- read the statement (PDF)

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.